Veradermics
MANE | NYSE
$132.72
-$6.97 (-4.99%)
Nov 2, 2026, 11:03 AM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q4 2024 Dec 31, 2024 |
|---|---|---|---|---|---|
Net Income | -23.5M | -27.23M | -21.85M | -20.1M | -5.66M |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a |
Stock-Based Compensation | 3.52M | 5.26M | 974K | 138K | 91K |
Other Working Capital | -43K | 2.81M | -2.74M | -892K | -199K |
Other Non-Cash Items | 5.54M | 554K | -154K | 392K | 1.09M |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | -43K | 251K | -2.6M | 559K | 844K |
Operating Cash Flow | -14.49M | -21.17M | -23.63M | -19.01M | -3.63M |
Capital Expenditures | -21K | n/a | -5K | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | -122.99M | -119.79M | n/a | n/a |
Sales Maturities Of Investments | n/a | 21.69M | 10.02M | 15M | n/a |
Other Investing Acitivies | -277.27M | n/a | n/a | n/a | n/a |
Investing Cash Flow | -277.29M | -101.3M | -109.78M | 15M | n/a |
Debt Repayment | n/a | n/a | n/a | n/a | -2.51M |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 442.7M | n/a | -1.5M | 1.05M | -283K |
Financial Cash Flow | 442.7M | 269.11M | 149.51M | 1.08M | 50.31M |
Net Cash Flow | 150.92M | 146.65M | 16.11M | -2.94M | 46.67M |
Free Cash Flow | -14.51M | -21.17M | -23.63M | -19.01M | -3.63M |
Adj. Free Cash Flow | -18.03M | -26.43M | -24.61M | -19.15M | -3.72M |
Maintenance CapEx | n/a | n/a | n/a | n/a | n/a |
Growth CapEx | -21K | n/a | -5K | n/a | n/a |
Owner Earnings | -14.49M | -21.17M | -23.63M | -19.01M | -3.63M |
Add to Watchlist
Select watchlists to add or remove MANE